HIMS Stock Options Traders Anticipate Significant Price Volatility Ahead of Earnings Hims & Hers Health (HIMS) stock options traders are signaling a substantial price swing ahead of the company’s upcoming earnings report, with market participants pricing in a potential 14.8% move. As of the latest data, the stock is trading near $26.25, and traders are using the $26 strike price as the at-the-money straddle. The call option for the $26 strike is priced at $2.11, while the put option is at $1.78, resulting in a total cost of $3.89. This pricing suggests a projected post-earnings range of approximately $22.36 to $30.14, reflecting heightened expectations for volatility. Analysts and traders are also observing similar implied moves across nearby strike prices. The $26.50 straddle is priced at $3.87, and the $27 straddle at $4.00, reinforcing the market’s anticipation of a significant price shift. The active positioning around these key strikes indicates that traders are preparing for a sharp reaction, with the $26 call showing 1,391 contracts traded compared to 740 puts. Open interest at the $26 strike is nearly balanced, with 3,167 calls and 3,136 puts outstanding. However, the $26.50 strike leans more bullish, as 3,034 calls have been traded against only 319 puts. The options market’s focus on volatility suggests that investors are bracing for a substantial earnings outcome, rather than a minor price fluctuation. The balanced open interest near the $26 strike implies readiness for a move in either direction, while the heavier call volume at $26.50 points to increased optimism about potential upside.#hims_hers_health #hims #earnings_report #stock_options #wall_street_analysts
Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud Hims & Hers Health Inc. saw its stock price rise sharply after Novo Nordisk A/S agreed to end its public dispute with the company through a new partnership. The deal involves Novo Nordisk’s weight-loss medications being sold on the Hims platform, marking a resolution to their ongoing conflict. According to a source familiar with the matter, the two companies plan to formally announce the partnership on Monday. This agreement follows a similar deal from last year, which Novo abruptly canceled after Hims continued marketing and selling generic versions of Novo’s drugs. The feud had drawn significant attention, with both companies accusing each other of unfair practices. The new partnership is expected to address these tensions by allowing Novo to distribute its obesity treatments through Hims’s digital health platform. This move could expand access to weight-loss medications for patients while providing Hims with additional revenue streams. Analysts suggest the deal reflects a broader trend of pharmaceutical companies seeking to leverage digital health platforms to reach consumers directly. The resolution of the public feud has also bolstered investor confidence in Hims & Hers, contributing to its stock surge. The company has long positioned itself as a leader in the digital wellness space, offering products ranging from hair loss treatments to sexual health solutions. With the addition of Novo’s obesity drugs, Hims aims to strengthen its portfolio and compete more effectively in the crowded health tech market. The partnership underscores the growing importance of digital platforms in healthcare, as companies seek to bypass traditional distribution channels and engage consumers directly.#hims_hers #novonordisk #hims_hers_health_inc #hims #novonordisk_as
